Analysis of temporal and spatial diversity of RAS gene mutations in metastatic colorectal cancer
Not Applicable
Recruiting
- Conditions
- Metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000053017
- Lead Sponsor
- Kanagawa Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Colitic cancer
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The incidence of NeoRAS wild-type
- Secondary Outcome Measures
Name Time Method 1. Percentage of RAS status mutations during chemotherapy. 2. Percentage of neo-RAS wild-type anti-EGFR antibodies used. 3. RAS mutation rates in tissue samples and liquid biopsy. 4. Overall survival, progression-free survival of neo RAS wild-type and RAS mutant